Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
BioSpace
The FDA's extension will give reviewers more time to review a major amendment to Biogen and Eisai's application for a subcutaneous induction formulation of Alzheimer's therapy Leqembi.
pharminent
May 8, 2026 (Last updated: May 10, 2026)
BioSpace
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi.